mefenamic acid 250 MG Oral Capsule
mefenamic acid
RxCUI: 829500
What the CMS Formulary Data Shows for mefenamic acid 250 MG Oral Capsule
Per the CMS 2026 Part D formulary file, mefenamic acid 250 MG Oral Capsule (RxNorm concept RXCUI 829500, generic name mefenamic acid) appears on 18 distinct formulary files spanning 221 Medicare Part D plan offerings - 4.4% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 1 to Tier 4, with a cross-plan average of Tier 2.8.
Real-world access to mefenamic acid 250 MG Oral Capsule depends on utilization management as much as tier placement: 0% of covering formularies require prior authorization. 0% require step therapy. 5.6% apply quantity limits.
Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 138 Part D beneficiaries filled mefenamic acid 250 MG Oral Capsule in 2023, with total plan-and-beneficiary spending of $65,861 and an average per-beneficiary annual cost of $477.25. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry mefenamic acid 250 MG Oral Capsule today.
Coverage Details
- Formularies covering
- 18
- Plans covering
- 221
- Coverage rate
- 4.4%
- Tier range
- Tier 1 – Tier 4
- Average tier
- Tier 3, Preferred Brand
Restrictions
- Prior authorization required
- 0% of formularies
- Step therapy required
- 0% of formularies
- Quantity limits
- 5.6% of formularies
2023 Medicare Spending
- Beneficiaries
- 138
- Total spending
- $65,861
- Avg per beneficiary
- $477.25
Tier Distribution Across Plans
Medicare Advantage Plans (MA-PD) Covering mefenamic acid 250 MG Oral Capsule
100 Medicare Advantage plans with Part D drug coverage include this drug.
Frequently Asked Questions
Is mefenamic acid 250 MG Oral Capsule covered by Medicare Part D?
Yes, mefenamic acid 250 MG Oral Capsule is covered by 221 Medicare Part D plans (4.4% of all Part D formularies).
What tier is mefenamic acid 250 MG Oral Capsule on Medicare Part D plans?
mefenamic acid 250 MG Oral Capsule averages Tier 2.8 across Part D plans, ranging from Tier 1 to Tier 4.
Does mefenamic acid 250 MG Oral Capsule require prior authorization?
0% of Part D formularies require prior authorization for mefenamic acid 250 MG Oral Capsule. Step therapy: 0%. Quantity limits: 5.6%.
How much does Medicare spend on mefenamic acid 250 MG Oral Capsule?
In 2023, total Medicare Part D spending on mefenamic acid 250 MG Oral Capsule was $65,861, covering 138 beneficiaries. The average spend per beneficiary was $477.25.
Read our methodology - how this data is sourced, computed, and verified.